Form 4: IN8BIO Executive Acquires Stock Options

Lawrence Lamb, EVP and CSO of IN8BIO, acquired stock options for 306,750 shares on February 5, 2025.

Summary

• Lawrence Lamb, the EVP and CSO of IN8BIO, INC., filed a Form 4 on February 7, 2025.
• The filing reports a transaction that occurred on February 5, 2025, where Lamb acquired employee stock options.
• These options grant him the right to buy 306,750 shares of IN8BIO's common stock at an exercise price of $0.29 per share.
• The options vest over time, with 25% vesting on February 5, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The option grant itself doesn't inherently indicate positive or negative performance, but rather incentivizes future performance.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future prospects.

Future Outlook

The vesting schedule indicates a long-term commitment from the executive, as the options vest over a period of several years.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates